caa a22 4500 469074434 CHVBK 20180323132931.0 cr unu---uuuuu 170328e19920901xx s 000 0 eng 10.1007/BF01741548 doi (NATIONALLICENCE)springer-10.1007/BF01741548 Clinical studies on cell-mediated immunity in patients with renal cell carcinoma: interleukin-2 and interferon-γ production of lymphocytes [Elektronische Daten] [Shinichi Ikemoto, Seiji Wada, Masato Kamizuru, Nobuyuki Hayahara, Taketoshi Kishimoto, Masanobu Maekawa] Summary: The authors examined interleukin-2 (IL-2) production and interferon γ (IFNγ) production of peripheral blood mononuclear cells in 28 patients with renal cell carcinoma and 17 control subjects. The peripheral blood was obtained prior to the initiation of therapeutic procedures. The patients were divided into two groups according to tumor size, ⩽5 cm and >5 cm. The production of IL-2 and IFNγ was measured by immunoradiometric assay. As a result, in the patients with tumors >5 cm, IL-2 and IFNγ production was impaired. However, in the patients with tumors ⩽5 cm, IFNγ production was enhanced, though IL-2 production was not significantly different from that of the control subjects. There was no significant correlation between IL-2 production and IFNγ production. Springer-Verlag, 1992 Renal cell carcinoma nationallicence Cell-mediated immunity nationallicence Interleukin-2 nationallicence Interferon γ nationallicence Ikemoto Shinichi Department of Urology, Osaka City University Medical School, 1-5-7 Asahi-machi, Abeno-ku, 545, Osaka, Japan aut Wada Seiji Department of Urology, Osaka City University Medical School, 1-5-7 Asahi-machi, Abeno-ku, 545, Osaka, Japan aut Kamizuru Masato Department of Urology, Osaka City University Medical School, 1-5-7 Asahi-machi, Abeno-ku, 545, Osaka, Japan aut Hayahara Nobuyuki Department of Urology, Osaka City University Medical School, 1-5-7 Asahi-machi, Abeno-ku, 545, Osaka, Japan aut Kishimoto Taketoshi Department of Urology, Osaka City University Medical School, 1-5-7 Asahi-machi, Abeno-ku, 545, Osaka, Japan aut Maekawa Masanobu Department of Urology, Osaka City University Medical School, 1-5-7 Asahi-machi, Abeno-ku, 545, Osaka, Japan aut Cancer Immunology, Immunotherapy Springer-Verlag 34/5(1992-09-01), 289-293 0340-7004 34:5<289 1992 34 262 https://doi.org/10.1007/BF01741548 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741548 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ikemoto Shinichi Department of Urology, Osaka City University Medical School, 1-5-7 Asahi-machi, Abeno-ku, 545, Osaka, Japan aut NATIONALLICENCE 700 1- Wada Seiji Department of Urology, Osaka City University Medical School, 1-5-7 Asahi-machi, Abeno-ku, 545, Osaka, Japan aut NATIONALLICENCE 700 1- Kamizuru Masato Department of Urology, Osaka City University Medical School, 1-5-7 Asahi-machi, Abeno-ku, 545, Osaka, Japan aut NATIONALLICENCE 700 1- Hayahara Nobuyuki Department of Urology, Osaka City University Medical School, 1-5-7 Asahi-machi, Abeno-ku, 545, Osaka, Japan aut NATIONALLICENCE 700 1- Kishimoto Taketoshi Department of Urology, Osaka City University Medical School, 1-5-7 Asahi-machi, Abeno-ku, 545, Osaka, Japan aut NATIONALLICENCE 700 1- Maekawa Masanobu Department of Urology, Osaka City University Medical School, 1-5-7 Asahi-machi, Abeno-ku, 545, Osaka, Japan aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 34/5(1992-09-01), 289-293 0340-7004 34:5<289 1992 34 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer